Antibody Fragment Conjugate Mixture for Targeted Therapy
A blend of antibody fragments and conjugates for precise immune targeting in autoimmune diseases. It is a mixed, non-retail immunological product, including antibody conjugates as per Chapter 30 Note 2, so it falls under tariff item 3002.14.00.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| π¨π³China | Free | β | Free |
| π²π½Mexico | Free | β | Free |
| πΊπΈUnited States | Free | β | Free |
| π©πͺGermany | Free | β | Free |
| π―π΅Japan | Free | β | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If put up in measured doses or for retail sale
Retail forms would be classified under the retail-sale subheading.
If used as diagnostic reagents for patient administration
Opacifying preparations and diagnostic reagents fall under heading 3006.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item β and can price the duty on it in the same conversation.
Import Tips & Compliance
β’ Ensure the mixture is not in retail packaging or measured doses to qualify for this item
β’ Provide a detailed composition sheet showing antibody fragments and conjugates for customs classification
β’ Verify if the product requires a medical device or drug license from Health Canada
Related Products under Tariff item 3002.14.00
Adalimumab Reference Product Bulk
A bulk mixed form of adalimumab (Humira) monoclonal antibody for rheumatoid arthritis treatment, supplied for further dilution. It is not in measured doses or retail packings, and qualifies as a mixed immunological product under chapter note 2.
Antibody Fragment Conjugate Mixture
A mixed biotechnological preparation containing antibody fragments and conjugates, designed for targeted drug delivery in immunology. It is supplied in bulk, not put up in measured doses or retail packings, and qualifies as a mixed immunological product under the chapter's definition.
Bevacizumab Biosimilar Mixture
A bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. It is not put up in measured doses or retail packings, and is classified as a mixed immunological product per chapter note 2.
Biotech Antibody and Chemokine Solution
A mixed solution of monoclonal antibodies (MAB) and chemokines for inflammation control, supplied in bulk for further processing. It is not in measured doses or retail packings, and is classified as a mixed immunological product per chapter note 2.
Blended Interferon-Alpha and Interleukin-2 Preparation
A mixed solution of recombinant interferon-alpha (IFN-Ξ±) and interleukin-2 (IL-2) for immunotherapy in viral infections and cancer. It is supplied in bulk, not in measured doses or retail packings, and qualifies as a mixed immunological product under chapter note 2.
Blended Interferon-Alpha and Interleukin-2 Therapy
A mixed preparation of recombinant interferon-alpha and interleukin-2 for treating viral infections and boosting immune response in immunotherapy. It is a mixed immunological product (interferons and interleukins) not in retail sale, so it is classified under tariff item 3002.14.00.